1. Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.
Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment. A, schematic representation of treatment schedule. B, in vivo trafficking of transferred pmel-1 T cells. Luciferase-expressing pmel-1 T cells (1 × 106) were transferred into mice bearing established 7-day MC38/gp100 tumors. DC vaccine and IL-2 treatment were conducted as previously described. Mice were intraperitoneally injected with 250 μg either control antibody or anti-PD-1 Ab on days 0, 2, and 4 after T-cell transfer. Imaging was conducted on day 6 after T-cell transfer. Data shown were from representative mice. C, quantitative imaging analysis of transferred T cells in tumor-bearing mice. Intensities of the luciferase signal at tumor sites in all tumor-bearing mice are depicted (N = 4 per group). D, tumor growth curve of MC38/gp100 tumor-bearing mice receiving anti–PD-1 Ab with or without adoptive T-cell transfer (N = 5 per group). E, tumor growth curve of B16 tumor-bearing mice receiving anti–PD-1 Ab with or without adoptive T-cell transfer (N = 5 per group).
Weiyi Peng et al. Cancer Res 2012;72:
©2012 by American Association for Cancer Research